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AbstrACt 
Objective To examine the role of the Five Factor Model 
(FFM) personality traits in reporting the development 
of adverse drug reactions (ADRs) when controlling for 
sociodemographic variables and health status.
Design Prospective cohort study.
setting The Estonian Biobank of the Estonian Genome 
Centre, University of Tartu.
Participants 814 women and 543 men (mean age=47.9 
years; SD=15.2) who after the initial enrolment in the 
Estonian Biobank were re-contacted for follow-up 
purposes about 5.3 years after the enrolment and for 
whom both self- and informant-reported personality data 
were available.
Main outcome measure Participants who did not report 
having any ADRs at baseline but who reported ADRs at the 
follow-up about 5.3 years later versus participants who 
did not report any ADRs at either time point. The reports of 
developing ADRs were predicted from the FFM personality 
traits after statistically controlling for sociodemographic 
variables (age, gender and education), baseline indicators 
of health status (number of diagnoses and medicines 
taken, body mass index and blood pressure), and the 
change in health status between the two measurements.
results The results of a hierarchical binary logistic 
regression analysis showed that participants who reported 
the development of ADRs between the two measurements 
had higher levels of conscientiousness, were more likely 
to be women, were taking more medicines at baseline and 
had a higher increase in the number of medicines taken 
during the study period than participants who did not 
report any ADRs at either time point (all p values <0.05). 
Higher neuroticism (p=0.067) and a higher number of 
diagnosed diseases at baseline (p=0.053) also made 
marginal contributions to predicting the development of 
ADRs.
Conclusions This study shows for the first time that 
higher levels of conscientiousness and neuroticism are 
associated with reporting the development of ADRs.
IntrODuCtIOn
Adverse drug reactions (ADRs) are very 
common and represent significant issues in 
healthcare, as they, for example, may negatively 
impact treatment adherence. ADRs have 
been defined as ‘an appreciably harmful or 
unpleasant reaction, resulting from an interven-
tion related to the use of a medicinal product, 
which predicts hazard from future administra-
tion and warrants prevention or specific treat-
ment, or alteration of the dosage regimen, or 
withdrawal of the product’ (p1255).1 ADRs 
have a major effect on public health resulting 
in a broad range of clinically severe conditions 
(including a significant numbers of deaths) as 
well as in an increased burden on the health-
care system due to a high number of hospital-
isations and outpatient visits.2–4 The prevalence 
of ADRs among the general population is not 
well established,5 but the few existing studies 
have shown that the 1-month prevalence of 
strengths and limitations of the study
 ► Differently from earlier studies, we used a rela-
tively large population-based adult sample, which 
allows us to generalise our findings to the general 
population.
 ► The prospective nature of our study (the participants 
were followed up for a mean period of 5.3 years) let 
us examine not just the associations between per-
sonality and ADRs, but also the role of the FFM per-
sonality traits in reporting the development of ADRs 
during the period of the study.
 ► When examining the role of the FFM personality 
traits in reporting the development of ADRs, we con-
trolled for the relevant sociodemographic (gender, 
age and education) and health indicators (number of 
medicines taken, number of diagnoses, body mass 
index and blood pressure) that may affect the re-
porting and development of ADRs.
 ► We were not able to account for the severity of the 
reported ADRs, which has been found to be one of 
the main motivations for consumers to report ADRs.
 ► All ADRs were self-reported by the participants of 
the study during a computer-assisted personal 
interview.
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suspected or self-reported ADRs in the general public is 
about 6% to 8%.6–8 
All medicines can cause ADRs, the severity of which 
may range from minor to life-threatening. However, the 
propensity and likelihood of developing and reporting 
ADRs does not only depend on the chemical formula 
or the pharmacological action of the drug, but also on 
a multitude of other factors, as has been shown, for 
instance, by the prevalence of reported ADRs in studies 
examining the placebo and nocebo effects of drugs.9 10 
Up to now, factors associated with the reporting of the 
development of ADRs include genetics,11 gender,12 age,13 
polypharmacy,14 drug metabolism15 and several other 
individual and social factors.16
A less studied factor that may be relevant for reporting 
on the development of ADRs relates to people’s person-
ality characteristics. Personality traits are usually under-
stood as enduring tendencies to feel, think and behave 
in a characteristic way in similar life situations17 and there 
has been an increasing amount of literature showing that 
personality has an important impact on people’s health 
and health-related behaviour.18–20 The most prevalent 
personality framework is the Five-Factor Model (FFM),21 
which proposes neuroticism, extraversion, openness to 
experience (openness), agreeableness and conscien-
tiousness as the main factors of personality differences. 
Most notably, low neuroticism22 23 and high conscien-
tiousness24–26 have been most frequently shown to predict 
longevity and better physical and mental health. There is 
also compelling evidence showing that personality traits 
shape people’s subjective interpretations of their health 
status in important ways.27 People high in neuroticism, 
for instance, are more likely to report different symptoms 
and medical problems28 and to ask for medical help29 
than people low in neuroticism. Higher conscientiousness 
has been found to be related to a bias toward reporting 
disease among persons who do not meet clinical criteria 
for disease,30 while people with higher levels of agreeable-
ness are more likely to get pain relief from a placebo.31
To the best of our knowledge, only a few studies have 
specifically examined the relationship between person-
ality traits and the reporting or developing of ADRs. These 
studies—that have mostly been conducted in small (65 to 
120 participants) samples of non-representative partic-
ipants, either patients or healthy volunteers in phase 1 
drug trials—have shown that people with higher levels of 
neuroticism32 33 and/or lower levels of extraversion34 are 
likely to report more ADRs than less neurotic and more 
extraverted individuals. Therefore, affirming the role of 
personality traits in developing and reporting suspected 
ADRs in the general population is of vital importance.
the aim of the present study
The aim of the present study was to examine the role of 
the FFM personality traits in reporting the development 
of ADRs in a large population-based adult sample when 
controlling for relevant sociodemographic and health 
indicators. All ADRs were self-reported by the participants 
of the study during the computer-assisted personal inter-
view (CAPI) conducted by a clinician.
Our study went beyond earlier research in several 
important aspects. (1) Differently from earlier studies, 
we used a relatively large population-based adult sample, 
which allows us to generalise our findings to the general 
population. (2) The prospective nature of our study (the 
participants were followed up for a mean period of 5.3 
years) let us examine not just the associations between 
personality and self-reported ADRs, but also the role of 
the FFM personality traits in developing ADRs during 
the period of the study. (3) In addition to self-reports of 
personality, we employed informant-reports of person-
ality by knowledgeable others to minimise the common 
method bias (ie, response tendencies within raters) 
and thereby increase both the reliability and validity 
of our findings.35 (4) When examining the role of the 
FFM personality traits in reporting the development of 
suspected ADRs, we controlled for the relevant sociode-
mographic (gender, age and education) and health indi-
cators (number of medicines taken, number of diagnoses, 
body mass index and blood pressure) that may affect the 
reporting and development of ADRs.
MethOD
sample
Participants for the present study came from the Estonian 
Biobank cohort that is a volunteer-based sample of the Esto-
nian resident adult population of the Estonian Genome 
Centre at the University of Tartu (EGCUT).36 The partici-
pants were recruited randomly by general practitioners 
(GPs), physicians or other medical personnel in private prac-
tices and clinics or in the recruitment offices of the EGCUT. 
Each participant signed an informed consent form (available 
at www. biobank. ee) and the GPs or physicians performed a 
standardised health examination of the participants. Partici-
pants also donated blood samples for DNA, white blood cells 
and plasma tests as well as completed a CAPI together with 
a clinician on health-related topics such as lifestyle, diet and 
clinical diagnoses.36
Our sample for the current study includes 1357 people 
(814 women, 60.0%) who joined the Estonian Biobank 
cohort during the years of 2002–2010, who were followed 
up longitudinally by the EGCUT in the years of 2007–2014, 
and for whom both self- and informant-reported person-
ality data were available. At baseline (T1), the mean age 
of the participants was 47.9 years (SD=15.2, ranging from 
18 to 86 years). About 11% of the participants had basic 
(n=151), 23.7% (n=322) had secondary, 33.8% (n=458) 
had vocational secondaryi and 31.4% of the participants 
(n=426) had higher education. The second health exam-
ination and the completion of the CAPI (ie, T2) took 
place on average 5.3 years (SD=3.2) after T1.36
i Vocational secondary education means that besides vocational training 
the student also acquires upper secondary education.
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The mean age of informants (996 women, 75.1%) was 
45.2 (SD=16.1) years. On average, the informants had 
known the targets for 27.4 (SD=14.6) years. About 41% 
of the informants were spouses or partners, 24.8% were 
parents, 14.4% were friends and 18.7% were other rela-
tives (eg, children and siblings) or acquaintances.
MAterIAls
Personality
The Estonian version of the NEO Personality Inven-
tory-3 (NEO PI-3)37 was used to assess personality. The 
NEO PI-3 has 240 items that measure 30 personality 
facets, which are grouped into the five FFM domains—
neuroticism, extraversion, openness, agreeableness and 
conscientiousness—such that each domain score is a 
composite of six facet scores. Neuroticism is a general 
tendency to experience negative emotions such as 
sadness, anger, hostility and fear. People who score high 
on neuroticism are prone to anxiety and psychological 
distress, whereas people scoring low on neuroticism 
are usually emotionally stable and well-adjusted. Extra-
version is a tendency to experience joy and other posi-
tive emotions, to seek out stimulation, to be active and 
sociable. People who score high on openness to experi-
ence are usually intellectually curious, attentive to their 
inner feelings, open to new ideas and opportunities. 
People scoring low on openness tend to be conserva-
tive and conventional, preferring the ‘old way’ of doing 
things rather than the ‘new’. Agreeableness is mostly 
about interpersonal tendencies referring to people’s 
altruistic, sympathetic, cooperative and trustful nature. 
Finally, conscientiousness refers to individual differ-
ences in an active process of planning, organising, and 
carrying out tasks. People scoring high in conscien-
tiousness are thorough, reliable, and task-oriented and 
goal-oriented, whereas people scoring low in consci-
entiousness are more laid-back and less anxious about 
setting and reaching their goals.38
Participants completed the self-report form and 
informants the observer-report form of the Estonian 
NEO PI-3. The items were answered on a 5-point scale 
(0=false/strongly disagree … 4=true/strongly agree). Most 
of the participants (88%) completed the personality 
inventory in the same year as T2 or during the year after 
T2 (10%). Nearly all informants (96.5%) completed 
the NEO PI-3 in the same year as the participants. The 
descriptive statistics of the scales, including Cronbach 
alphas, are shown in online supplementary table S1. 
Self- and informant-reports of the NEO PI-3 personality 
traits correlated with each other in the expected magni-
tude39 40: Pearson rs were 0.55 for neuroticism, 0.65 for 
extraversion, 0.61 for openness, 0.46 for agreeableness 
and 0.50 for conscientiousness (all p values <0.001). 
For all subsequent analyses, the mean score of self- and 
informant-ratings across the five domain scales was used 
to minimise the common method bias due to individual 
response biases.35
Adverse drug reactions
The participants were asked whether there are any medi-
cines that have caused them ADRs during their whole 
life and if yes, what were the specific suspected ADRs. All 
ADRs were self-reported by the participants of the study 
during the CAPI conducted by a clinician. The medicine 
that the respondent reported as causing their ADR was 
coded according to the Anatomical Therapeutic Chem-
ical (ATC) classification system (http://www. whocc. no/ 
atc_ ddd_ index). The suspected ADRs caused by medi-
cines were coded using the 10th revision of the Interna-
tional Statistical Classification of Diseases and Related 
Health Problems (ICD-10) classification system.41
health indicators
All measures of current health status described below 
were retrieved from the EGCUT, which contains data 
gathered from the databases of healthcare institutions 
and registries, as well as from the information provided 
by the participant, using the above-mentioned CAPI. 
Anthropometric measures (ie, height and weight) and 
blood pressure were measured by EGCUT recruiters36 at 
the end of the CAPI. The means of the health indicators at 
T1 and T2, and the difference and correlations between 
the measurements are shown in the online supplemen-
tary table S2.
Clinical diagnoses. For each participant, the number of 
diagnoses recorded in the Estonian Health Insurance 
Fund (EHIF) for the year of data collection (both at T1 
and T2) was used. The EHIF covers the costs of health 
services required by eligible persons in the case of illness 
and is the only organisation in Estonia dealing with 
compulsory health insurance (https://www. haigekassa. 
ee/ en).
Use of medicines. First, participants were asked during 
the CAPI which diseases they had been diagnosed with 
and which medicines they had used during the previous 
2 months in connection with these illnesses (‘Which 
medicines have you used during the last 2 months in 
connection with diagnosed diseases?’). Later, the partici-
pants were also asked ‘Which medicines do you use regu-
larly (which have not been discussed earlier)?’ The total 
number of taken medicines, either regularly or in connec-
tion with specific diseases during the last 2 months, was 
used in all later analyses.
Blood pressure. Systolic and diastolic blood pressure (BP) 
were measured in a sitting position at the end of the CAPI 
interview both at T1 and T2.
Body mass index (BMI). BMI was calculated on the basis 
of objectively measured weight and height during the 
CAPI at T1 and T2 as weight/height2 (kg/m2).
statistical analyses
Pearson product–moment correlation coefficients were 
computed to examine correlations between self- and 
informant-reports of the NEO PI-3 personality traits. 
Cronbach alphas were calculated to examine internal 
consistency of the NEO PI-3 five domain scales. A one-way 
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analysis of variance was used to examine the mean differ-
ences in the continuous variables between the partic-
ipants who reported developing ADRs between T1 and 
T2 and who did not report any medicines causing ADRs 
at either time point. Gender and education differences 
between the participants who reported developing ADRs 
between T1 and T2 and who did not report any medicines 
causing ADRs at either time point were tested using the χ2 
test. A hierarchical binary logistic regression analysis was 
performed to examine the role of the FFM personality 
traits in reporting the development of ADRs between T1 
and T2 when controlling for sociodemographic variables, 
baseline measurements of health status and the change in 
health status between the two measurements. In logistic 
regression analysis, higher education was defined as the 
reference or baseline category (1) for the education vari-
able. All analyses were conducted using IBM SPSS Statis-
tics software, V.24.
Patient and public involvement
Patients and public were not involved in the development 
of the research question and the selection of outcome 
measures.
results
the reported frequency of ADrs
At baseline (T1), there were 162 participants (11.9% of 
the total sample) who reported taking medicines that had 
caused them  ADRs.ii Among those who reported taking 
medicines that had caused them ADRs at T1, the average 
number of ADRs per participant was 1.5 (SD=1.4), with 
ii Almost a third (30.3%) of reported medicines at baseline fell into 
the category of anti-infective for systemic use (J) with beta-lactam anti-
bacterials and penicillins (J01C) being the most frequently reported 
medicines to cause ADRs (17.4%). The other most frequent groups of 
medicines (18.3%) causing ADRs were medicines acting on the nervous 
system (N), especially other analgesics and antipyretics (N02B, 8.3%) 
and local anaesthetics (N01B, 5.0%); medicines affecting the cardiovas-
cular system (C, 11.9%), especially selective calcium channel blockers 
with mainly vascular effects (C08C, 4.1%) and plain ACE inhibitors 
(C09A, 3.2%); and medicines affecting musculoskeletal systems (M, 
10%), especially anti-inflammatory and antirheumatic products, non-ste-
roids (M01A, 7.3%). At T2, the most frequently mentioned medicines 
causing ADRs were anti-infective for systemic use (J, 31.1%, especially 
J01C: beta-lactam antibacterials and penicillins, 17.8%); medicines 
acting on the nervous system (N, 16.6%; especially N02B: other analge-
sics and antipyretics, 5.9% and N01B: local anaesthetics, 4.8%); medi-
cines affecting musculoskeletal systems (M, 14.3%; especially M01A: 
anti-inflammatory and antirheumatic products, non-steroids, 11.9%) 
and medicines affecting the cardiovascular system (C, 13.1%, especially 
C08C: selective calcium channel blockers with mainly vascular effects, 
3.3% and C09A: plain ACE inhibitors, 2.9%). The three most frequent 
ATC classes of medicines reported causing ADRs in our study were the 
same as what was found in the analysis of spontaneous reporting of 
ADRs in the UK ‘Yellow Card Scheme’.48 Even more importantly, as the 
most frequent ATC classes of medicines that were reported in our study 
were the same at T1 and T2, it is unlikely that the type of medicines 
would have had a strong independent influence on the development of 
ADRs between T1 and T2.
about 70% of participants reporting one ADR, 17% two 
ADRs and the remaining three or more ADRs.
At T2, there were roughly twice as many participants 
(n=329, 24.1% of the total sample) than at T1 who 
reported taking medicines that had caused them ADRs; 
difference between time points: χ2(1)=201.9, p<0.001. 
On average, 1.6 ADRs (SD=1.2) were reported per 
participant at T2, with 66% of participants reporting 
one, 22% two and the remaining participants three or 
more ADRs. The frequency of specific ADRs (as coded 
by ICD-10) both at T1 and T2 is shown in the online 
supplementary table S3.
There were 217 participants who did not report ADRs 
caused by medicines at T1, but did so at T2. In our 
further analyses, this group of participants (n=217) was 
compared against those participants (n=978) who did 
not report any medicines causing ADRs at either time 
point. A χ2 test showed that respondents who developed 
ADRs between T1 and T2 were predominantly women 
and had less likely higher education compared with 
people who did not report any ADRs either at T1 or 
T2 (see table 1). The results of the analyses of variance 
showed that people who developed ADRs between T1 
and T2 had higher levels of neuroticism and conscien-
tiousness, were older, had been diagnosed with more 
diseases (both at T1 and T2), were taking more medi-
cines (both at T1 and T2) and had higher BMI and 
systolic BP (only at T2) than those who did not report 
ADRs at either time point (all differences significant at 
p<0.05). Finally, people who developed ADRs by T2 had 
also a bigger increase in the number of medicines taken 
and in the level of BMI from T1 to T2 as compared with 
those who never reported any ADRs (all differences 
significant at p<0.05).
Next, we conducted a hierarchical binary logistic 
regression analysis in order to predict the reporting on 
the development of ADRs between T1 and T2 from the 
FFM personality traits when controlling for sociodemo-
graphic variables, baseline measurements of health status 
and the change in health status between the two measure-
ments. Only those variables were included in the model 
as predictors on which there were significant differences 
between people who reported developing ADRs between 
T1 and T2 versus participants who did not report any 
ADRs at either time point.
The following nine variables entered in three blocks 
were included in the binary logistic hierarchical regres-
sion model in order to predict the reporting of the devel-
opment of ADRs: (1) baseline age, gender and education; 
(2) number of diagnoses at T1, number of medicines 
taken at T1, change in the number of medicines taken 
from T1 to T2 and change in BMI from T1 to T2; and (3) 
neuroticism and conscientiousness at T2.
The nine variables together explained 11.6% of the varia-
tion (as indicated by the Nagelkerke pseudo R2) in the depen-
dent variable (ie, developing ADRs between T1 and T2). 
Being a woman, taking more medicines at T1, an increase 
in the number of medicines taken from T1 to T2 and higher 
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levels of conscientiousness were all associated with increased 
odds of developing suspected ADRs from medicines between 
T1 and T2 (p values<0.05). A higher number of diagnosed 
diseases (p=0.053) and higher neuroticism (p=0.067) also 
made marginal contribution to predicting the reporting of 
the development of ADRs (see table 2).
DIsCussIOn
In the current study, we examined the role of the FFM 
personality traits in reporting the development of 
suspected ADRs in a large-scale adult cohort of >1300 
individuals, when controlling for sociodemographic 
variables and health status. The findings of our analysis 
Table 1 Differences in FFM personality traits, health and sociodemographic indicators between participants who reported 
developing ADRs between T1 and T2 versus participants who did not report ADRs at either time point
No ADRs either at T1 or T2
(n=978)
Reported developing ADRs 
between T1 and T2 (n=217)
F df P valuesM SD M SD
NEO PI-3 domain scales (T2)
  Neuroticism 81.96 21.36 85.99 22.53 6.17 1193 0.013
  Extraversion 102.21 23.08 100.54 23.21 0.92 1193 0.337
  Openness to experience 97.59 18.10 97.68 17.40 0.00 1193 0.944
  Agreeableness 122.21 16.72 121.66 17.95 0.19 1193 0.666
  Conscientiousness 125.32 20.06 128.99 18.49 6.10 1193 0.014
Health Indicators
  Number of EHIF diagnoses (T1) 4.91 4.18 6.76 5.26 31.55 1193 <0.001
  Number of EHIF diagnoses (T2) 4.96 4.36 6.80 5.04 29.61 1193 <0.001
  Change in the number of EHIF diagnoses from T1 to 
T2
0.05 3.94 0.06 5.05 0.00 1193 0.954
  Number of medicines taken (T1) 1.20 1.90 1.85 2.30 19.47 1193 <0.001
  Number of medicines taken (T2) 2.09 2.52 3.47 3.44 46.34 1193 <0.001
  Change in the number of medicines taken from T1 to 
T2
0.89 2.13 1.62 2.87 18.13 1193 <0.001
  BMI (T1) 26.83 5.08 27.27 5.09 1.32 1193 0.251
  BMI (T2) 27.81 5.62 28.66 5.69 4.03 1191 0.045
  Change in BMI from T1 to T2 0.97 2.59 1.37 2.76 4.11 1191 0.043
  Systolic BP (T1) 127.27 17.13 129.46 17.43 2.88 1192 0.090
  Systolic BP (T2) 133.29 19.71 136.37 20.56 4.25 1192 0.039
  Change in systolic BP from T1 to T2 6.04 19.03 6.83 20.20 0.30 1191 0.584
  Diastolic BP (T1) 78.61 10.87 79.08 10.93 0.33 1192 0.564
  Diastolic BP (T2) 83.01 11.28 83.52 10.88 0.38 1192 0.539
  Change in diastolic BP from T1 to T2 4.40 12.17 4.44 13.06 0.00 1191 0.971
Sociodemographic variables (T1)
Age 46.79 15.57 50.60 13.11 11.23 1193 <0.001
No ADRs either at T1 or T2 
(n = 978)
Reported developing ADRs 
between T1 and T2 (n = 217)
Χ2 df P valuesn % n %
Sociodemographic variables (T1)
Gender 24.37 1 <0.000
  Females 538 55.0 159 73.3
  Males 440 45.0 58 26.7
Education 8.53 3 0.036
  Basic 121 12.4 19 8.8
  Secondary 227 23.2 59 27.2
  Secondary vocational 326 33.3 87 40.1
  Higher 304 31.1 52 24.0
Number of EHIF diagnoses is the number of diagnoses recorded in the Estonian Health Insurance Fund for the year of data collection.
Number of medicines taken is the number of medicines taken during the previous 2 months, either regularly or for treating specific diseases.
ADR, adverse drug reaction; BMI, body mass index; BP, blood pressure; EHIF, Estonian Health Insurance Fund; FFM, Five-Factor Model; NEO PI-3, 
NEO Personality Inventory-3; T1, first measurement; T2, second measurement (on average 5.3 years after T1). 
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showed that participants who reported developing ADRs 
during the study had significantly higher levels of consci-
entiousness (p=0.019) as well as marginally higher levels 
of neuroticism (p=0.067), even when the relevant sociode-
mographic and health variables were taken into account.
Extensive research has revealed that conscientious-
ness is a strong lifelong predictor of longevity and good 
health.25 42 There are multiple pathways by which conscien-
tiousness is associated with health, but most likely consci-
entiousness promotes health by engaging in healthier 
behaviours and by choosing healthier situations and 
environments, thereby minimising different small health 
risks.26 Among other things, conscientiousness has been 
found to be related to more frequent visits to the general 
practitioner,29 meaning that conscientious individuals are 
more vigilant about their health and pay greater attention 
to their health problems. This may explain why conscien-
tious individuals in our study were more likely to develop 
and report ADRs, as they may perceive any bodily reac-
tions as an important health risk factor.
Another personality trait that was significantly associ-
ated and, after controlling for relevant sociodemographic 
and health-related variables, marginally predicted the 
development and reporting of ADRs in our study was 
neuroticism. Similarly to low conscientiousness, high 
neuroticism is a strong and robust predictor of different 
mental and physical health problems as well as of the 
frequency of health service use.22 Again, there are prob-
ably different pathways through which neuroticism influ-
ences health, but it is possible that the development of 
ADRs among people high in neuroticism is related to 
their enhanced physiological responses that result from 
chronic over-activation of the autonomic nervous system18 
or from greater sympathetic and hypothalamic–pituitary–
adrenal reactivity.22 It has been also found that people 
high in neuroticism respond more strongly to sensations 
of pain and discomfort and, as a result, they are more 
likely to notice and attend to bodily sensations and minor 
discomforts, including unfounded symptoms without a 
physiological basis.28 30 Also, conscientiousness is related 
to a bias toward reporting disease among individuals who 
actually do not meet clinical criteria for disease, meaning 
that highly conscientious individuals ‘may use lower 
criteria to establish illness because they are more cautious 
about their health and eager to report illness so they may 
obtain an early diagnosis and treatment’ (p. 376).30 Thus, 
it is possible that individuals high in conscientiousness 
and high in neuroticism are over-reporting ADRs due 
to heightened levels of self-awareness, pain sensitivity or 
attentional focus, which results in heightened perception, 
over-reaction and vigilance about their bodily sensations 
and symptoms.30 43 High levels of neuroticism, accompa-
nied by high conscientiousness—a phenomenon called 
‘healthy neuroticism’—is however also seen as a good 
thing and is often associated with health benefits, as 
persons showing this combination are vigilant about their 
health and in case of any health problems take the neces-
sary action.44 45
Despite several strengths of this study, including the rela-
tively large population-based adult cohort, the prospec-
tive nature of our research, the use of both self-ratings 
and observer ratings of personality and the well-validated 
personality inventory, our research also had some limita-
tions. One of the main limitations of our study was that we 
were not able to account for the severity of the reported 
ADRs, which has been found to be one of the main moti-
vations for consumers to report ADRs.46 However, large-
scale studies in Denmark and the UK have shown that 
the general public and physicians tend to report similar 
proportions of serious or severe ADRs47 48 and, therefore, 
we have no reason to believe that taking into account the 
severity of ADRs would have impacted our results in any 
substantial way.
Another limitation of our study relates to the fact the 
design of our study did not allow for causality assess-
ment of ADRs, which is the approved method used for 
estimating the strength of relationship between drug(s) 
exposure and occurrence of ADRs.49 Instead, similarly 
to several earlier studies,7 8 our study examined people’s 
perceptions of an unwanted effect that they attributed to 
the use of a medicinal product. However, there is substan-
tial evidence that the quality of patient reports is similar 
to that of health professional reports.50 It has been also 
suggested that since only a small percentage of the ADRs 
that occur are reported by health professionals, it is diffi-
cult to establish the true occurrence and extent of ADRs 
in the general population, and therefore, more infor-
mation on the prevalence of experienced ADRs and on 
how patients themselves perceive ADRs, as was done in 
the present study, is needed.7 Therefore, we believe that 
our study makes a valuable contribution to this important 
stream of research, which has a strong potential to 
increase our knowledge about the possible harm of medi-
cines.50 51
The last limitation is that FFM personality traits were 
measured only once, and not at baseline, but at the 
follow-up about 5.3 years after the enrolment in the 
study. Although personality traits are not set in stone and 
people change in terms of personality traits across the life 
course,52 there is little reason to believe that the scores of 
neuroticism and conscientiousness would have dramati-
cally changed during our study53 54 or that having experi-
enced a difficult life event such as serious illness or injury, 
for instance, would have had strong effects on the scores 
of the FFM personality traits.28 55 On the contrary, it is 
personality traits that consistently predict the occurrence 
of different life events,56 including the onset of diseases.57
To sum up, the findings from the current study, exam-
ining personality traits in addition to sociodemographic 
and health indicators as predictors of reporting the 
development of ADRs in a large population-based adult 
sample, suggest that people with high levels of conscien-
tiousness and neuroticism are more likely to report on 
the development of ADRs, even after controlling for age, 
gender, medicine use and the number of diagnoses. As 
people with high levels of neuroticism are less likely to 
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volunteer to phase I drug trials34 58–60 than people with 
low levels of neuroticism, our results suggest that certain 
ADRs may remain undetected in phase I drug trials or the 
number of ADRs may be smaller than expected from the 
general population. Even more importantly, reporting 
of ADRs is no longer reserved for drug trials or health-
care professionals, but also available to the general public 
who have been invited as reporters of drugs and ADRs 
in many European and world countries.61 Thus, our find-
ings also suggest that people high in conscientiousness 
and neuroticism may be more likely to report ADRs using 
spontaneous reporting systems such as the Yellow Card 
Scheme in the UK,48 for instance. However, we should 
note that it is not entirely clear whether people high in 
conscientiousness and neuroticism (so-called’ healthy 
neurotics’) over-report ADRs (including physiologically 
unfounded symptoms) or whether’ healthy neurotics’ are 
actually adequate in reporting of ADRs and it is those low 
in conscientiousness and neuroticism who significantly 
under-report potential ADRs. To that aim, future longitu-
dinal studies need to be performed, in which participants 
high and low on these personality traits are followed in 
their health course for a longer period of time. Neverthe-
less, our findings are among the first to demonstrate that 
personality traits such as conscientiousness and neurot-
icism are not merely associated with reporting ADRs,62 
but may also serve as risk factors for the development of 
ADRs on top of different sociodemographic and health 
indicators.
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